Solidion(US:STI) Globenewswire·2025-12-31 13:00Core Insights - Hydreight Technologies Inc. has entered the at-home STI pre-screening market through an exclusive distribution agreement with Health Screen Collective, aiming to address a significant public health challenge in the U.S. [1][3] Company Overview - Hydreight is a digital health platform that provides on-demand care, pharmacy fulfillment, and enterprise healthcare services across the U.S. [1] - The company has established a network of over 3,000 nurses and 300 doctors, along with a pharmacy network, enabling healthcare professionals to deliver services directly to patients [14]. Market Opportunity - Approximately one in five people in the U.S. is living with an STI, with millions of new infections occurring annually, highlighting the need for accessible screening solutions [3][4]. - The at-home STI pre-screening market is expected to grow rapidly, driven by public health guidelines and patient behavior [11]. Product Details - Hydreight will exclusively distribute HSC's at-home STI pre-screen testing kits, which have already secured around 50,000 pre-orders, with deliveries starting in early 2026 [2][12]. - The testing kits provide results in minutes using validated lateral-flow immunoassay technology, allowing for private sample collection at home [5][7]. Clinical Integration - The kits are designed to facilitate a seamless transition from pre-screening to licensed medical review, confirmatory testing, clinical consultation, and treatment coordination [8][9]. - This integrated workflow enhances access and continuity of care, transforming at-home testing into a connected digital healthcare experience [9]. Strategic Importance - The high-frequency nature of STI screening aligns with Hydreight's platform-first strategy, which aims to drive repeat engagement and long-term platform utilization [11][13]. - The initial demand for the pre-screening kits reflects interest from enterprise partners and healthcare operators seeking scalable solutions [12].